Federal Register / Vol. 80, No. 76 / Tuesday, April 21, 2015 / Notices 22233 

of compliance with 39 U.S.C. 3633(a), 

and an application for non-public 

treatment of certain materials. It also 

filed supporting financial workpapers. 

II. Notice of Commission Action 

The Commission establishes Docket 

No. CP2015–59 for consideration of 

matters raised by the Notice. 

The Commission invites comments on 

whether the Postal Service’s filing is 

consistent with 39 U.S.C. 3632, 3633, or 

3642, 39 CFR part 3015, and 39 CFR 

part 3020, subpart B. Comments are due 

no later than April 22, 2015. The public 

portions of the filing can be accessed via 

the Commission’s Web site (http://

www.prc.gov). 

The Commission appoints Curtis E. 

Kidd to serve as Public Representative 

in this docket. 

III. Ordering Paragraphs 

It is ordered: 

1. The Commission establishes Docket 

No. CP2015–59 for consideration of the 

matters raised by the Postal Service’s 

Notice. 

2. Pursuant to 39 U.S.C. 505, Curtis E. 

Kidd is appointed to serve as an officer 

of the Commission to represent the 

interests of the general public in this 

proceeding (Public Representative). 

3. Comments are due no later than 

April 22, 2015. 

4. The Secretary shall arrange for 

publication of this order in the Federal 

Register. 

By the Commission. 

Shoshana M. Grove, 

Secretary. 

[FR Doc. 2015–09031 Filed 4–20–15; 8:45 am] 

BILLING CODE 7710–FW–P 

REAGAN-UDALL FOUNDATION FOR 

THE FOOD AND DRUG 

ADMINISTRATION 

[BAC 416404] 

Annual Public Meeting; Reagan-Udall 

Foundation for the Food and Drug 

Administration 

ACTION: Notice of annual meeting. 

SUMMARY: The Reagan-Udall Foundation 

for the Food and Drug Administration 

(FDA), which was created by Title VI of 

the Food and Drug Administration 

Amendments Act of 2007, is 

announcing its annual public meeting. 

The purpose of this meeting is to 

provide an opportunity for the 

Foundation to engage with its 

stakeholders and receive public input 

on its efforts. The meeting will include 

an organizational update, project 

updates, panel discussion, and open 

Q & A. 

DATES: The public meeting will be held 

on May 15, 2015, from 10 a.m. until 12 

noon. Registration to attend the meeting 

and requests for oral presentation must 

be received by May 8, 2015. See the 

SUPPLEMENTARY INFORMATION section for 

information on how to register for the 

meeting. 

ADDRESSES: The public meeting will be 

held The Pew Charitable Trusts 

Conference Center, 901 E St. NW., 

Washington, DC 20004. Entrance for the 

meeting is located on 9th St. NW., 

between F St. NW. and E St. NW. 

FOR FURTHER INFORMATION CONTACT: Jane 

Reese-Coulbourne, Reagan-Udall 

Foundation for the FDA, 202–828–1205, 

Meetings@ReaganUdall.org. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Reagan-Udall Foundation for the 

FDA (the Foundation) is an independent 

501(c)(3) not-for-profit organization 

created by Congress to advance the 

mission of FDA to modernize medical, 

veterinary, food, food ingredient, and 

cosmetic product development; 

accelerate innovation; and enhance 

product safety. With the ultimate goal of 

improving public health, the 

Foundation provides a unique 

opportunity for different sectors (FDA, 

patient groups, academia, other 

government entities, and industry) to 

work together in a transparent way to 

create exciting new research projects to 

advance regulatory science. 

The Foundation acts as a neutral third 

party to establish novel, scientific 

collaborations. Much like any other 

independently developed information, 

FDA evaluates the scientific information 

from these collaborations to determine 

how Reagan-Udall Foundation projects 

can help the Agency to fulfill its 

mission. 

The Foundation’s programmatic 

efforts are designed to improve the 

existing scientific tools (methods) used 

to evaluate products as well as foster the 

development of innovative tools and 

approaches. This is exemplified in the 

Foundation’s projects including: The 

Innovation in Medical Evidence 

Development and Surveillance Program, 

which develops and evaluates methods 

for using observational electronic health 

care data for postmarket evidence 

generation, including postmarket safety 

surveillance; the PredicTox Project, 

which applies systems biology to 

develop mechanistic models to predict 

adverse events; and the Critical Path to 

Tuberculosis Drug Regimens Project, 

which looks at novel approaches to 

development and review of tuberculosis 

combination therapies. Additionally, 

the Foundation is establishing 

regulatory science fellowships as part of 

its broader education efforts aimed at 

building capacity in regulatory science. 

II. Meeting Attendance and 

Participation 

A. Registration 

If you wish to attend the meeting, 

visit: http://goo.gl/GX6ysw. Please 

register for the meeting by May 8, 2015. 

Seating may be limited, so early 

registration is recommended. 

Registration is free and will be on a firstcome, first-served basis. Onsite 

registration on the day of the meeting 

will be based on space availability. 

B. Requests for Oral Comments 

Interested persons may present 

comments at the public meeting. 

Comments will be scheduled to begin 

approximate at 11:40 a.m. Time allotted 

for comments may be limited to 3 

minutes, dependent on number of 

requests received. Those desiring to 

make oral comments should notify Jane 

Reese-Coulbourne (see FOR FURTHER

INFORMATION CONTACT) by May 8, 2015. 

Please include a brief statement of the 

general nature of the comments they 

wish to present along with your name, 

address, telephone number, and email. 

The agenda for the public meeting 

will be posted on the event registration 

page: http://goo.gl/GX6ysw and the 

Reagan-Udall Web site: http://goo.gl/

aSVymH. 

C. Written Comments 

Interested persons may submit either 

electronic or written comments to the 

Foundation at any time to Comments@

ReaganUdall.org, or by mail to the 

Reagan-Udall Foundation for the FDA, 

1025 Connecticut Ave. NW., Suite 1000, 

Washington, DC 20036. Please include 

your name, address, telephone number, 

and email when making comments. 

III. Post-Meeting Materials 

The Foundation plans to make 

meeting materials and meeting 

recording available to the public after 

the meeting. Once available, these 

materials will be posted at http://goo.gl/ 

aSVymH. 

Dated: April 15, 2015. 

Jane Reese-Coulbourne, 

Executive Director, Reagan-Udall Foundation 

for the FDA. 

[FR Doc. 2015–09072 Filed 4–20–15; 8:45 am] 

BILLING CODE 4164–04–P 


tkelley on DSK3SPTVN1PROD with NOTICES